Regular ArticleReversal of Multidrug-Resistance Phenotype by Surfactants: Relationship to Membrane Lipid Fluidity
Abstract
Previous studies have suggested that multidrug resistance (MDR) reversal by polyoxyethylene surfactants involves alterations in plasma membrane lipid physical state of resistant cells as one of the possible mechanism(s). To date, however, a detailed and critical examination of the relationship between membrane lipid fluidity and MDR reversal by these surfactants has not been performed. In the present studies, therefore, a series of experiments were conducted to critically examine the role of membrane lipid physical state in MDR reversal by employing a unique class of clinically important nontoxic lipophilic surfactants and the KB-8-5-11 drug-resistant cell line. MDR reversal was assessed by rhodamine-123 uptake. The effect of surfactants on plasma membrane lipid fluidity of these cells was assessed utilizing a fluorescence polarization technique with fluorophores DPH, TMA, DPH, 2-AS, and 12-AS. Our studies demonstrated that: (i) in vitro addition of active MDR-reversing surfactants (Solutol HS-15, Tween 40, and Cremophor EL, 10 μg/ml each) decreased lipid fluidity of isolated crude plasma membranes of resistant cells; (ii) the inactive surfactants (octylglucoside, hecameg) failed to influence membrane lipid fluidity; (iii) cells grown in the presence of active surfactants also exhibited a decreased plasma membrane lipid fluidity as measured with intact cells utilizing the probe TMA.DPH; and (iv) active surfactants did not influence lifetimes of the excited state of the fluorophores, These findings demonstrate that decrease of the plasma membrane lipid fluidity of KB 8-5-11 resistant cells may be one of the important mechanism(s) of MDR reversal by polyoxyethylene surfactants.
References (0)
Cited by (150)
Toxicokinetic and toxicodynamic mixture effects of plant protection products: A case study
2023, Regulatory Toxicology and PharmacologyAuthorisation of ready to use plant protection products (PPPs) usually relies on the testing of acute and local toxicity only. This is in stark contrast to the situation for active substances where the mandatory data set comprises a most comprehensive set of studies. While the combination of certain active ingredients and co-formulants may nevertheless result in increased toxicity of the final product such combinations have never been evaluated systematically for complex and long-term toxicological endpoints. We therefore investigated the effect of three frequently used co-formulants on the toxicokinetic and toxicodynamic of the representative active substance combination of tebuconazol (Teb) and prothioconazol (Pro) or of cypermethrin (Cpm) and piperonyl butoxide (Pip), respectively. With all four active substances being potential liver steatogens, cytotoxicity and triglyceride accumulation in HepaRG were used as primary endpoints. Concomitantly transcriptomics and biochemical studies were applied to interrogate for effects on gene expression or inhibition of CYP3A4 as key enzyme for functionalization. Some of the tested combinations clearly showed more than additive effects, partly due to CYP3A4 enzyme inhibition. Other effects comprised the modulation of the expression and activity of steatosis-related nuclear key receptors. Altogether, the findings highlight the need for a more systematic consideration of toxicodynamic and toxicokinetic mixture effects during assessment of PPPs.
Brain targeting of venlafaxine HCl as a hydrophilic agent prepared through green lipid nanotechnology
2021, Journal of Drug Delivery Science and TechnologyThis study aimed to improve venlafaxine HCl brain delivery using solid lipid nanoparticles (SLNs) made by an ultrasonication method. The impact of the ratio of two surfactants (Tween:Span) on nanoparticle behaviors and their efficiency was examined to achieve optimal brain delivery for venlafaxine. To study the solid-state of venlafaxine in SLNs and detect any potential interactions between the drug and other formulation excipients, PCS, TEM, ATR-FTIR, and DSC were employed. By reducing the HLB (Hydrophilic–lipophilic balance) of the binary surfactants, the particle size of SLN increased. The optimized nanoparticles showed an average particle size of 311.33 ± 9.29 nm when the HLB of the ratio of the surfactants (Tween:Span) was adjusted to 8. The zeta potential of SLNs decreased from −15.90 ± 0.70 to −6.95 ± 0.42 mV when the HLB of the system was reduced from 14 to 8. According to the results, the highest entrapment efficiency of 76.05 ± 1.42% was observed for the formulation with the largest particle size and the lowest HLB value (HLB 8). DSC analysis showed that venlafaxine was in an amorphous state in SLN. The findings of the ATR-FTIR also excluded any chemical interactions between excipients and the drug. Venlafaxine-SLN had a prolonged release pattern, according to the in vitro diffusion process. Venlafaxine oral absorption from SLN was also substantially higher than venlafaxine solution after single-dose oral administration of venlafaxine preparations. This research demonstrated that the venlafaxine-SLN might be employed as a potential nano-vehicle for venlafaxine brain delivery and potentially opens up new avenues for depression treatment.
Morphological transition of M. tuberculosis and modulation of intestinal permeation by food grade cationic nanoemulsion: In vitro-ex vivo-in silico GastroPlus™ studies
2020, Journal of Drug Delivery Science and TechnologyThe study aimed to investigate rifampicin (RIF) loaded cationic nanoemulsion (NE) for increased efficacy, facilitated intestinal permeability and GastroPlus™ based prediction. Formulations were prepared and characterized for robustness to dilution, cloud point and stability to varied pH. Morphological transition of M. tuberculosis H37 Rv was studied by a transmission electron microscopy (TEM), % inhibition study and cytoplasmic content analysis. The ex vivo permeation and confocal laser scanning microscopy (CLSM) studies were conducted using duodenum, jejunum and ileum. Results of robustness ensured stability to dilution, pH and temperature (˃ 37 °C). The Smix (surfactant to co-surfactant) ratio (2:1 and 3:1) possessed maximized % inhibition due to LAB and AC8. The Peff values of cationic NE were 2.25, 1.96 and 2.0 fold higher than DS (drug solution) for duodenum, jejunum and ileum, respectively, whereas enhancement ratios were 2.25-, 1.94- and 2.0 fold higher than DS. A CLSM showed 3.22-, 2.89-, and 1.1 fold higher % fluorescence intensity from duodenum, jejunum and ileum, respectively. GastroPlus™ predicted 100% regional absorption of RIF-cationic NE and considerable effect of globular size, permeability and nanonization on pharmacokinetics (PK) parameters. Conclusively, the cationic NE can be a promising approach for increased efficacy of RIF and augmented oral absorption to control tuberculosis.
Considerations for Determining Direct Versus Indirect Functional Effects of Solubilizing Excipients on Drug Transporters for Enhancing Bioavailability
2020, Journal of Pharmaceutical SciencesExcipients used in drug formulations at clinically safe levels have been considered to be pharmacologically inert; however, numerous studies have suggested that many solubilizing agents may modulate drug transporter activities and intestinal absorption. Here, the reported interactions between various solubilizing excipients and drug transporters are evaluated to consider various potential underlying mechanisms. This forms the basis for debate in the field in regard to whether or not the effects are based on “direct” interactions or “indirect” consequences arising from the role of the excipients. For example, an increase in apparent drug solubility can give rise to saturation of transporters according to Michaelis-Menten kinetics. This is also drawing the attention of regulatory agencies as they seek to understand the role of formulation additives. The continued application of excipients as a tool in solubility enhancement is crucial in the drug development process, creating a need for additional data to verify the proposed mechanism behind these changes. A literature review is provided here with some guidance on other factors that should be considered to delineate the effects that arise from direct physiological interactions or indirect effects. The results of such studies may aid the rational design of bioavailability-enhancing formulations.
Shedding light on interaction of so called inactive ingredients (excipients) with permeability-glycoprotein
2019, Journal of Drug Delivery Science and TechnologyPermeability glycoprotein (P-gp) is a 170 kDa membrane transporter from the category of efflux pumps, which is situated at the apical site of epithelial membrane. P-gp is known to efflux diverse classes of chemical compounds including anticancer agents, antibiotics, steroidal compounds and many more. Numerous strategies have been used to inhibit the efflux of such compounds via efflux transporters including co-administration with P-gp inhibitors, chemical modifications and others, with limited success. Excipients (so called inactive ingredients) are intentionally added in drug formulations to alter characteristics of drug. Nowadays, there is increasing interest in investigating these traditionally used excipients for their efflux pump inhibitory potential, as they have been reported to cause subtle changes, that can affect transporter proteins (efflux pumps) on cell membrane. Many reviews have explained the role of specific P-gp inhibitors for improved drug delivery, however there is not much data when it comes to exploring an excipient for its inherent function and P-gp inhibitory potential. This review will shed light on current status of excipients, which can be used to modulate membrane transporter inhibition potential and discuss the mechanism involved in it. Certain preparations, formulated using such excipients which enhances drug absorption and minimize related toxicity, will be also discussed.
In vitro digestion models to evaluate lipid based drug delivery systems; present status and current trends
2019, Advanced Drug Delivery ReviewsDuring the past two decades, a range of in vitro models simulating the digestion processes occurring in the stomach and small intestine have been developed to characterize lipid based drug delivery systems (LbDDSs). This review describes the presently existing range of in vitro digestion models and their use in the field of oral drug delivery. The models are evaluated in terms of their suitability to assess LbDDSs, and their ability to produce in vitro - in vivo correlations (IVIVCs).
While the pH-stat lipolysis model is by far the most commonly utilized in vitro digestion model in relation to characterizing LbDDSs, a series of recent studies have shown a lack of IVIVCs limiting its future use. Presently, no single in vitro digestion model exists which is able to predict the in vivo performance of various LbDDSs. However, recent research has shown the potential of combined digestion-permeation models as well as species specific digestion models.